COMMUNIQUÉS West-GlobeNewswire

CHMP recommends RYBREVANT®▼ (amivantamab) in combination with LAZCLUZE®▼ (lazertinib) for the first-line treatment of patients with EGFR-mutated advanced non-small cell lung cancer

15/11/2024 - 16:12

The amivantamab plus lazertinib combination regimen offers potential to provide new standard of care as first-line option for adult patients with advanced NSCLC with EGFR ex19del or L858R substitution mutations 1 In the [...]

Altimmune Presents New Data on the Effect of Pemvidutide on Inflammatory Lipids in Subjects with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) at The Liver Meeting® 2024

15/11/2024 - 17:00

Weekly subcutaneous doses of pemvidutide resulted in robust reductions in cardio-inflammatory, hepato-inflammatory and atherosclerotic lipids Findings support the potential benefit of pemvidutide on co-morbidities of [...]

Atea Pharmaceuticals Presents Multiple New Datasets Supporting the Combination of Bemnifosbuvir and Ruzasvir for the Treatment of Hepatitis C Virus at AASLD’s The Liver Meeting 2024

15/11/2024 - 17:00

BOSTON, Nov. 15, 2024 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for [...]

Akero Therapeutics to Showcase New Analyses of Phase 2b HARMONY Study in Presentations at 75th Annual AASLD The Liver Meeting® 2024

15/11/2024 - 17:00

-- Over 40% of participants treated with EFX 50mg for 96 weeks, compared with 0% for placebo, showed regression of liver fibrosis by all of three orthogonal measures: (1) ≥1-stage fibrosis improvement by NASH-CRN stage [...]

Eccogene Announces Positive Phase 1 Data for Oral THR-β Full Agonist and Oral SSAO Inhibitor in Late-Breaking Poster Presentations at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting®

15/11/2024 - 17:00

Both ECC4703 and ECC0509 demonstrated best-in-class potential, with favorable safety and tolerability profiles, clear target engagement and encouraging efficacy signals BOSTON and SHANGHAI, Nov. 15, 2024 (GLOBE NEWSWIRE [...]

Iqirvo® (elafibranor) montre des données d’efficacité et de tolérance sur une période allant jusqu’à trois ans chez les patients atteints de CBP avec une amélioration de la fatigue et du prurit

15/11/2024 - 17:00

Ipsen met en avant 3 nouvelles présentations ainsi que 8 abstracts dans le cadre de son portefeuille de maladies cholestatiques rares du foie au congrès 2024 de l’AASLD. L’utilisation d’Iqirvo a été approuvée aux États- [...]

Iqirvo® (elafibranor) data shows efficacy and safety for up to 3 years in patients with PBC with improvements in fatigue and pruritus

15/11/2024 - 17:00

Ipsen presents 3 late-breaking presentations and 8 abstracts across rare cholestatic liver disease portfolio at AASLD 2024 Iqirvo approved for use in the U.S. in June 2024, in the E.U. in September 2024 and in the U.K. [...]

Bluejay Therapeutics Reports Best-in-Class Monoclonal Antibody BJT-778 Achieved 100% Virologic Response and Up To 78% Combined Virologic Response and ALT Normalization as Monotherapy in Participants With Chronic Hepatitis D (CHD)

15/11/2024 - 17:00

Phase 2 study results to be presented at The Liver Meeting ® 2024 of AASLD BJT-778 900 mg dosed every four weeks showed promising efficacy by Week 24: 100% virologic response with 50% of participants with undetectable [...]

Arbutus and Barinthus Bio Announce New Data from the IM-PROVE II Trial Showing that the Addition of Nivolumab Increased Rates of HBsAg Loss in People with Chronic Hepatitis B

15/11/2024 - 17:01

Significantly greater mean declines in HBsAg levels (p <0.017) were seen in those receiving imdusiran, VTP-300 and low-dose nivolumab compared to other cohorts assessed previously 23% of participants receiving [...]

Arbutus and Barinthus Bio Announce New Data from the IM-PROVE II Trial Showing that the Addition of Nivolumab Increased Rates of HBsAg Loss in People with Chronic Hepatitis B

15/11/2024 - 17:01

Significantly greater mean declines in HBsAg levels (p <0.017) were seen in those receiving imdusiran, VTP-300 and low-dose nivolumab compared to other cohorts assessed previously 23% of participants receiving [...]

Barinthus Bio Announces Results From Ongoing Phase 2b Chronic Hepatitis B Trial, Including Achievement of Functional Cure and HBsAb Seroconversion

15/11/2024 - 17:02

Eight participants achieved HBsAg loss at any time. Two participants met criteria for functional cure. Two participants who discontinued NUC therapy seroconverted to HBsAb positivity. OXFORD, United Kingdom, Nov. 15, [...]

Arbutus’ Imdusiran Achieves Functional Cure in cHBV Patients when Combined with a Short Course of Interferon

15/11/2024 - 17:02

50% of patients who had baseline HBsAg levels less than 1000 IU/mL achieved functional cure in Cohort A1 of the IM-PROVE I Phase 2a clinical trial Overall, in Cohort A1, 25% of patients achieved functional cure Data to [...]

Award-winning Mind Food Body Ltd vows to end Destructive Workplace Eating Habits

15/11/2024 - 18:35

KENT, United Kingdom, Nov. 15, 2024 (GLOBE NEWSWIRE) -- Mind Food Body Ltd. , led by Hanna Longstaff, The Eating Behaviour Expert, has launched a new range of corporate wellness solutions designed to address one of the [...]

GROUPE SAFE - Mise à disposition du Rapport Financier Annuel 2023

15/11/2024 - 19:57

Mise à disposition du Rapport Financier Annuel 2023 Fleurieux-sur-l’Arbresle - France - le 15 novembre 2024 à 20h . Safe SA (la « Société ») annonce avoir déposé auprès de l’Autorité des Marchés Financiers et mis à la [...]

Inventiva présentera lors de la session « late-breaker » de l'AASLD The Liver Meeting®, les résultats de l'analyse finale de la Phase 2 évaluant la combinaison de lanifibranor avec empagliflozine chez des patients atteints de MASH et DT2

15/11/2024 - 22:00

Les résultats seront présentés lundi 18 novembre par poster lors de la session « late-breaker » du congrès de l’AASLD The Liver Meeting® à San Diego. L'étude LEGEND a atteint son critère principal d'efficacité en [...]

Inventiva will present data from the final analysis of the Phase 2 study evaluating the combination of lanifibranor with empagliflozin in patients with MASH and T2D at the AASLD The Liver Meeting® late-breaker session

15/11/2024 - 22:00

Data will be presented on Monday, November 18 th as a late breaker poster at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® 2024 in San Diego. LEGEND achieved its primary efficacy [...]

Adverum Biotechnologies Announces Webcast to Report 52-Week LUNA Phase 2 Clinical Data and 4-Year OPTIC Clinical Data, and to Provide Key Pivotal Program Design Elements

15/11/2024 - 22:05

– Investor & analyst webcast, including a key opinion leader panel, to be held Monday, November 18 th at 7:30 a.m. EST REDWOOD CITY, Calif., Nov. 15, 2024 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: [...]

Calidi Biotherapeutics Announces Closing of $7.5 Million Public Offering of Common Stock

15/11/2024 - 22:05

SAN DIEGO, Nov. 15, 2024 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE American: CLDI) (“Calidi”), a clinical-stage biotechnology company developing a new generation of targeted antitumor virotherapies, today [...]

Ascendis Pharma Reports Third Quarter 2024 Financial Results

14/11/2024 - 22:01

– YORVIPATH launching in U.S. with product availability expected mid-January 2025; ex-U.S. YORVIPATH revenue of €8.5 million in Q3 – TransCon CNP NDA submission for achondroplasia planned for Q1 2025 followed by MAA [...]